deltatrials
Completed PHASE2/PHASE3 NCT00476112

A Phase II/III Tolerance and Efficacy Study of RSD1235 in Patients With Atrial Flutter

A Phase II/III Prospective, Randomized, Double-Blind, Placebo-Controlled, Multi-Centred Tolerance and Efficacy Study of RSD1235 in Patients With Atrial Flutter

Sponsor: Advanz Pharma

Conditions Atrial Flutter
Interventions Vernakalant Injection 20 mg/mL
Updated 8 times since 2017 Last updated: Mar 31, 2008 Started: Aug 31, 2003 Primary completion: Sep 30, 2004 Completion: Sep 30, 2004

This PHASE2/PHASE3 trial investigates Atrial Flutter and is currently completed. Advanz Pharma leads this study, which shows 8 recorded versions since 2003 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Change History

8 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2/PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2/PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2/PHASE3

    Phase: PHASE2_PHASE3 → PHASE2/PHASE3

  4. Apr 2022 — Jul 2024 [monthly]

    Completed PHASE2_PHASE3

  5. Jan 2021 — Apr 2022 [monthly]

    Completed PHASE2_PHASE3

▶ Show 3 earlier versions

  1. Dec 2019 — Jan 2021 [monthly]

    Completed PHASE2_PHASE3

  2. Jun 2018 — Dec 2019 [monthly]

    Completed PHASE2_PHASE3

  3. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2_PHASE3

    First recorded

Aug 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Advanz Pharma
  • Astellas Pharma US, Inc.
Data source: Advanz Pharma

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aalborg, Denmark, Calgary, Canada, Copenhagen, Denmark, Edmonton, Canada, Esbjerg, Denmark, Glostrup Municipality, Denmark, Hamilton, Canada, Hellerup, Denmark, Herlev, Denmark, Hjørring, Denmark and 10 more location s